Last update 08 May 2025

Virtuoso Binco, Inc.

Private Company|United States

Overview

Tags

Neoplasms
Antibody Fragment-Drug Conjugates (FDCs)

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Antibody Fragment-Drug Conjugates (FDCs)1
Top 5 TargetCount
PARP1(Poly (ADP-Ribose) polymerase 1)1

Related

2
Drugs associated with Virtuoso Binco, Inc.
VP-301
Target
CD38 x ICAM-1
Mechanism
CD38 inhibitors [+1]
Active Org.
Virtuoso Therapeutics, Inc.Virtuoso Therapeutics, Inc.
Originator Org.
Virtuoso Binco, Inc.
Active Indication
Multiple Myeloma
Inactive Indication
Refractory Multiple Myeloma [+1]
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
WO2023131219
Patent Mining
Target
PARP1
Mechanism-
Active Org.
Virtuoso Binco, Inc.
Originator Org.
Virtuoso Binco, Inc.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Virtuoso Binco, Inc.
NCT05698888
/ TerminatedPhase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
100 Clinical Results associated with Virtuoso Binco, Inc.
Login to view more data
0 Patents (Medical) associated with Virtuoso Binco, Inc.
Login to view more data
100 Deals associated with Virtuoso Binco, Inc.
Login to view more data
100 Translational Medicine associated with Virtuoso Binco, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
WO2023131219
 ( PARP1 )		Neoplasms
More
Discovery
VP-301
 ( CD38 x ICAM-1 )		Solid tumor
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free